Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Guardant Health's annualizedNet Income for the quarter that ended in Mar. 2025 was $-380.6 Mil. Guardant Health's average total tangible assets for the quarter that ended in Mar. 2025 was $1,405.1 Mil. Therefore, Guardant Health's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was -27.09%.
The historical rank and industry rank for Guardant Health's Return-on-Tangible-Asset or its related term are showing as below:
GH'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -39.58 Med: -26.86 Max: -9.93
Current: -27.3
During the past 9 years, Guardant Health's highest Return-on-Tangible-Asset was -9.93%. The lowest was -39.58%. And the median was -26.86%.
GH's Return-on-Tangible-Asset is ranked worse than 68.04% of 219
companies
in the Medical Diagnostics & Research industry
Industry Median: -4.07
vs GH: -27.30
Guardant Health Return-on-Tangible-Asset Historical Data
The historical data trend for Guardant Health's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Guardant Health's Return-on-Tangible-Asset
For the Diagnostics & Research subindustry, Guardant Health's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Guardant Health's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2025) net income data.
Guardant Health (NAS:GH) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Guardant Health Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Guardant Health's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your 